1 / 4

PMX 500 – CCRF-CEM Vincristine resistance – X-gal senescence staining

PMX 500 – CCRF-CEM Vincristine resistance – X-gal senescence staining. PMX 700 – U373V/M/VR cells. Is resistance to TMZ sustained following withdrawal of selection media?

michael-crosby
Download Presentation

PMX 500 – CCRF-CEM Vincristine resistance – X-gal senescence staining

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PMX 500 – CCRF-CEM Vincristine resistance – X-gal senescence staining

  2. PMX 700 – U373V/M/VR cells Is resistance to TMZ sustained following withdrawal of selection media? Grown with/without selection media (i.e. G418 for U373V and U373M or TMZ for U373VR) for 7d prior to setting up MTT assay. U373M cells maintain resistance despite 42 days w/o selection media.

  3. PMX 700 – PARP Potentiation HCT116 cells Treated with PARP inhibitor (ABT888, AG014699 or AZD2281) for 1 h followed by addition of Temozolomide (2, 5,10, 20 or 100 mM , PMX-000268, PMX-000495, PMX-000559, PMX-000561 or PMX-000568 (2, 5 or 10 mM) for a further 16 h. Media aspirated and replaced with drug free media. Cells allowed to grow for a further 72h prior to MTT assay. Growth curves generated and IC50’s calculated. PF50s calculated: PARP inhibitor IC50 PARP inhibitor + alkylating agent IC50 Toxicity of alkylating agents assessed. ** ** ** * ** * p<0.01 ** p<0.05 ANOVA vs control (Con) Con 2 5 10 20 100 1 2 5 10 1 2 5 10 1 2 5 10 1 2 5 10 1 2 5 10 (mM) Temozolomide PMX-000268 PMX-000495 PMX-000559 PMX-000561 PMX-000568

  4. PMX 700 – PARP Potentiation • 2 5 10 20 2 5 10 2 5 10 2 5 10 2 5 10 2 5 10 (mM) • Temozolomide PMX-000268 PMX-000495 PMX-000559 PMX-000561 PMX-000568 • 1 2 3 0 1 3 1 1 3 1 1 3 1 1 3 1 1 3 (n) ABT888 • 1 2 3 3 0 1 2 1 1 2 1 1 2 1 1 2 1 1 2 (n) AG014699/AZD2281

More Related